GSK plc research snapshot
GSK AI stock analysis currently sees GSK plc as a global biopharma company whose specialty medicines, vaccines, and late-stage pipeline are replacing older-product exposure. At the August 2, 2026 data cutoff, GSK last closed near $51.69 on July 31 and the mechanically verified market capitalization was about $104.18 billion. Q2 2026 results released July 28 showed core EPS up 9% while reported EPS fell sharply on a 1.3 billion pound impairment, and management announced a 1.9 billion pound annual savings program plus faster late-stage trial starts. This page is informational research, not investment advice.
Current price
$51.69
Market cap
$104.18 billion
AI score
67 / 100
Rating
Core growth intact; restructuring and 2028-2030 loss-of-exclusivity overhang
Trend status
Consolidating at the 50-day and 200-day moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | GSK turns research, trials, approvals, manufacturing, and global specialist sales into recurring revenue from prescription medicines and vaccines. | High |
| Moat | Patents, clinical evidence, regulatory capability, physician relationships, manufacturing, and global commercial scale create barriers, though each medicine ultimately faces competition and loss of exclusivity. | Medium-high |
| Management | Luke Miels and the leadership team should be judged by Accelerate Growth savings delivery, launch execution, acquisition discipline, debt management, and candid handling of setbacks such as the camlipixant impairment. | Medium |
| Financial trend | FY2025 turnover was 32.667 billion pounds, up 4% AER, with total EPS of 141.1p. Q2 2026 core EPS rose 9% to 50.5p, while reported EPS fell on the 1.3 billion pound camlipixant impairment. | High |
| Valuation | The reference framework indicates about 13.8x FY2025 translated EPS, about 16.3x trailing reported EPS, and about 11.2x free cash flow per ADR, with a 3.42% dividend yield. FX translation is an estimate. | Medium |
| Technical trend | The $51.69 quote sits near the $51.68 50-day and $51.61 200-day moving averages with an RSI near 48.7. The trend is neutral-to-constructive, but pharmaceutical shares can gap on clinical or policy news. | Medium |
| Risk level | Risk is medium-high because of the 2028-2030 dolutegravir loss of exclusivity, trial and regulatory outcomes, restructuring execution, pricing pressure, acquisition spending, debt, and exchange-rate exposure. | High |
| AI confidence | AI can organize filings, calculate scenario ranges, and identify monitoring variables. It cannot reliably convert a drug pipeline or market sentiment into an exact stock-price forecast. | High data confidence |
| Investment certainty | Medium certainty. The company has measurable franchise strength, but a suitable entry price depends on an investor view of pipeline replacement, pricing, leverage, and the required margin of safety. | Medium |
GSK AI stock forecast
The GSK AI stock forecast uses scenario ranges rather than a precise prediction. A three-year model audited with financial_rigor.py used the $51.69 quote, an approximately $3.75 FY2025 translated diluted EPS per ADR equivalent (141.1p per ordinary share at about $1.33 per pound), and separate growth and terminal-multiple assumptions. It produced a bearish area near $37 to $41, a base area near $60 to $65, and a bullish area near $80 to $85 before dividends.
$80 to $85 over three years
More likely if specialty medicines and vaccines keep double-digit growth, the expected 20+ phase III trial starts convert into approvals, bepirovirsen and oncology launches deliver, Accelerate Growth savings fund R&D without margin damage, and investors hold a multiple near 17x earnings.
$60 to $65 over three years
More likely if turnover grows near 3% to 5% per 2026 guidance, core EPS compounds in the 7% to 9% range, restructuring costs phase out, free cash flow supports dividends, buybacks, and selective deals, and the market values GSK near 14x earnings.
$37 to $41 over three years
More likely if dolutegravir and other loss-of-exclusivity losses arrive earlier or harder, late-stage assets such as bepirovirsen disappoint, payer pressure increases, restructuring or deal spending strains the balance sheet, or the multiple falls toward 10x.
GSK AI technical analysis
GSK AI technical analysis is neutral-to-constructive as of the July 31, 2026 close. StockAnalysis showed a $51.69 quote, a $51.68 50-day moving average, a $51.61 200-day moving average, and an RSI near 48.7. The support and resistance bands below are chart-review zones, not forecasts, and should be refreshed with live NYSE ADR data before any trade.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $51.69 | NYSE ADR close on July 31, 2026, used for market-cap and scenario math. |
| Near support | $50.50 to $51.00 | A zone just below the 50-day and 200-day average cluster, with a recent intraday low near $51.38. |
| Secondary support | $49.00 to $50.00 | A sustained close below this round-number zone would weaken the neutral-to-constructive read and call for a fresh chart review. |
| Near resistance | $53.50 to $54.00 | A move through this round-number area with volume would provide stronger continuation confirmation. |
| 52-week high | $61.70 | Upper reference of the 52-week range from $36.75 to $61.70. GSK is up about 33% over the past 52 weeks. |
| 50-day moving average | $51.68 | StockAnalysis statistics snapshot at the August 1, 2026 data check. |
| 200-day moving average | $51.61 | StockAnalysis statistics snapshot at the August 1, 2026 data check. |
| Momentum | RSI 48.71, neutral | Relative Strength Index near 48.7 is neutral. Momentum should be checked alongside earnings, trial, and regulatory calendars. |
| Volume | About 4.6 million shares per day | 20-day average volume is about 4.6 million shares. Require volume confirmation for a breakout because news-driven pharmaceutical moves can reverse quickly. |
| Volatility | Low beta, event-driven gaps | Five-year beta is about 0.30, but clinical results, approvals, pricing changes, and M&A can still create gaps that ordinary stops may not contain. |
| Invalidation | Sustained close below $50.00 | A sustained break below the $49 to $50 zone invalidates the neutral-to-constructive framework and requires new evidence. |
GSK AI trading strategy
The GSK AI trading strategy is a rules-based research framework for a large pharmaceutical ADR. It is not personal advice. Confirm live prices, volume, earnings, trial disclosures, filings, and your own position-size limits before acting.
Wait for GSK to hold above the $50.50 to $51.00 support band and then clear $53.50 to $54.00 with volume. Recheck the 50-day average, RSI, and the next results calendar using live data before treating the move as confirmed.
A sustained close below $50.00, reduced guidance, a material trial setback, or new pricing pressure invalidates the setup.
If GSK tests the $49 to $50 zone near the longer-term averages and stabilizes, compare the price reaction with specialty-medicine sales, vaccine demand, free cash flow, pipeline updates, and 2026 guidance before considering a rebound framework.
Do not average down without a predefined loss limit. Drug-development, regulatory, and acquisition events can create gaps that bypass ordinary stop assumptions.
Track specialty-medicine and vaccine sales, HIV and oncology launches such as Jideytro and neladalkib, bepirovirsen and other late-stage readouts, Accelerate Growth savings progress, 2026 turnover and core EPS guidance, free cash flow, net debt, capital returns, and policy or reimbursement changes.
Reduce confidence if growth increasingly depends on acquisitions, price, or a narrow set of products while dolutegravir loss-of-exclusivity losses and restructuring costs strain the earnings path.
Investment research summary
GSK converts scientific research, clinical development, regulatory approvals, manufacturing, and specialist commercial access into recurring sales of branded medicines and vaccines across specialty medicines, general medicines, and vaccines.
The moat combines intellectual property, clinical evidence, regulatory experience, physician and payer relationships, manufacturing know-how, and global distribution. It is strongest where a medicine remains differentiated and weakest near exclusivity loss or crowded competition, such as the dolutegravir franchise ahead of 2028-2030.
The thesis can fail if late-stage programs disappoint, the 2028-2030 dolutegravir loss of exclusivity hits earnings faster than expected, pricing pressure intensifies, restructuring disrupts delivery, acquisitions dilute returns, or debt limits capital-allocation flexibility.
Management should be assessed through the Accelerate Growth savings program, R&D returns and trial-start pace, launch execution, business-development discipline, balance-sheet management, capital returns, and candor about both clinical successes and setbacks such as the camlipixant impairment.
Aging populations, chronic disease, oncology innovation, prevention, and precision medicine support long-term demand. The same industry is shaped by binary trials, regulation, reimbursement, patent cycles, and political scrutiny of drug pricing.
The reference framework indicates about 13.8x FY2025 translated EPS, about 16.3x trailing reported EPS, and about 11.2x free cash flow per ADR at the cutoff quote, with a 3.42% dividend yield. Margin of safety depends on whether specialty medicines and the pipeline can offset predictable portfolio erosion and restructuring costs.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GSK price and market capitalization | $51.69 July 31, 2026 close and $104.18 billion market capitalization | StockAnalysis GSK overview | August 2, 2026 |
| Market capitalization verification | $104.16 billion from $51.69 x 2.015 billion ADR-equivalent shares, a 0.02% difference from the $104.18 billion reported input | financial_rigor.py market cap verification | August 2, 2026 |
| Q2 2026 results | Turnover 8.409 billion pounds, up 5% AER and 5% CER; core EPS 50.5p, up 9%; total EPS 10.8p, down 69% on a 1.3 billion pound camlipixant impairment and higher CCL charges | GSK Q2 2026 results announcement | July 28, 2026 |
| H1 2026 results | Turnover 16.038 billion pounds, up 3% AER and 5% CER; core operating profit 5.450 billion pounds (34.0% margin); core EPS 97.1p, up 6% AER and 9% CER; cash generated from operations 4.256 billion pounds | GSK Q2 2026 results announcement | July 28, 2026 |
| FY2025 results | Turnover 32.667 billion pounds, up 4% AER and 7% CER; total EPS 141.1p; core EPS 172.0p; net income of about 5.72 billion pounds attributable to shareholders | GSK FY2025 results and StockAnalysis cross-check | August 2, 2026 |
| Guidance and strategic program | FY2026 guidance of 3% to 5% turnover growth, 7% to 9% core operating profit growth, and 7% to 9% core EPS growth; 2031 sales outlook of more than 40 billion pounds; Accelerate Growth targets 1.9 billion pounds of annual savings by 2029; 70p dividend expected for FY2026; 2 billion pound buyback completed | GSK Q2 2026 results announcement | July 28, 2026 |
| Balance sheet at June 30, 2026 | Cash and cash equivalents of 3.105 billion pounds, total debt of about 18.238 billion pounds, net debt of about 15.13 billion pounds, and shareholders equity of 17.645 billion pounds | GSK Q2 2026 results and US dollar translation, with StockAnalysis cross-check | June 30, 2026 |
| Valuation check | About 13.78x FY2025 translated EPS ($3.75 per ADR at about $1.33 per pound), about 16.29x trailing reported EPS, about 11.2x free cash flow per ADR, and a 3.42% dividend yield. FX translation is an estimate and should be refreshed. | financial_rigor.py valuation verification | August 2, 2026 |
| Technical snapshot | $51.69 quote, $51.68 50-day moving average, $51.61 200-day moving average, RSI 48.71, beta 0.30, and 52-week range from $36.75 to $61.70 | StockAnalysis statistics | August 1, 2026 |
| Analyst consensus | Hold rating from 8 analysts with a $58.08 average price target, about 12% above the July 31, 2026 close | StockAnalysis analyst forecast | August 2, 2026 |
This GSK AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, trial results, approvals, pricing changes, acquisitions, restructuring, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
